Data gathered: April 15
Alternative Data for Puma Biotechnology
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 9 | Sign up | Sign up | Sign up |
| Sentiment | 50 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Employee Rating | 58 | Sign up | Sign up | Sign up |
| Google Trends | 14 | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 8 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 6,890 | Sign up | Sign up | Sign up |
| Twitter Followers | 87 | Sign up | Sign up | Sign up |
| Twitter Mentions | 19 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 19 | Sign up | Sign up | Sign up |
| Linkedin Employees | 240 | Sign up | Sign up | Sign up |
About Puma Biotechnology
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
| Price | $2.93 |
| Target Price | Sign up |
| Volume | 273,540 |
| Market Cap | $145M |
| Year Range | $2.25 - $3.83 |
| Dividend Yield | 0% |
| PE Ratio | 4.73 |
| Analyst Rating | 33% buy |
| Industry | Biotechnology |
In the news
 |
O Shaughnessy Asset Management LLC Acquires 56,202 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)April 12 - ETF Daily News |
|
Prudential Financial Inc. Grows Stock Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI)April 11 - ETF Daily News |
Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline PotentialApril 10 - SeekingAlpha |
|
|
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Bought by Sei Investments Co.April 8 - ETF Daily News |
 |
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 2 - Yahoo |
|
Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?March 27 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 81M | 48M | 32M | 20M | 25M | 0.410 |
| Q2 '24 | 47M | 38M | 9.1M | -4.5M | 730,000 | -0.090 |
| Q1 '24 | 44M | 35M | 8.4M | -4.8M | 1.7M | -0.100 |
| Q4 '23 | 69M | 47M | 22M | 12M | 19M | 0.260 |
| Q3 '23 | 53M | 38M | 14M | 5.8M | 12M | 0.120 |
Insider Transactions View All
| HUNT DOUGLAS M filed to sell 124,594 shares at $3.2. January 3 '25 |
| Ludwig Jeffrey Jerome filed to sell 108,951 shares at $3.2. January 3 '25 |
| AUERBACH ALAN H filed to sell 7,029,674 shares at $3.2. January 3 '25 |
| NOUGUES MAXIMO F filed to sell 152,295 shares at $3.2. January 3 '25 |
| MILLER MICHAEL PATRICK filed to sell 47,000 shares at $3.5. August 13 '24 |
Similar companies
Read more about Puma Biotechnology (PBYI) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Puma Biotechnology?
The Market Cap of Puma Biotechnology is $145M.
What is Puma Biotechnology's PE Ratio?
As of today, Puma Biotechnology's PE (Price to Earnings) ratio is 4.73.
What is the current stock price of Puma Biotechnology?
Currently, the price of one share of Puma Biotechnology stock is $2.93.
How can I analyze the PBYI stock price chart for investment decisions?
The PBYI stock price chart above provides a comprehensive visual representation of Puma Biotechnology's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Puma Biotechnology shares. Our platform offers an up-to-date PBYI stock price chart, along with technical data analysis and alternative data insights.
Does PBYI offer dividends to its shareholders?
As of our latest update, Puma Biotechnology (PBYI) does not offer dividends to its shareholders. Investors interested in Puma Biotechnology should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Puma Biotechnology?
Some of the similar stocks of Puma Biotechnology are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.